AbbVie Inc. (LON:0QCV)

Market Cap	276.69B
Revenue (ttm)	45.00B
Net Income (ttm)	3.39B
Shares Out	n/a
EPS (ttm)	1.91
PE Ratio	81.74
Forward PE	n/a
Dividend	4.96 (3.38%)
Ex-Dividend Date	Jan 15, 2025

Volume	123,965
Average Volume	5,471
Open	147.24
Previous Close	146.95
Day's Range	146.95 - 154.06
52-Week Range	131.22 - 167.80
Beta	0.60
RSI	48.39
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD